The relation of metabolic syndrome (MetS) with cardiovascular outcome may be less evident when preclinical cardiovascular disease is present. We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. MetS was defined by X2 risk factors plus hypertension: body mass index X30 kg/m 2 , high-density lipoprotein (HDL)-cholesterol o1.0/1.3 mmol/l (o40/ 50 mg/dl) (men/women), glucose X6.1 mmol/l (X110 mg/ dl) fasting or X7.8 mmol/l (X140 mg/dl) nonfasting or diabetes. Cardiovascular death and the primary composite end point (CEP) of cardiovascular death, stroke and myocardial infarction were examined. In MetS (1591 (19.3%) of 8243 eligible patients), low HDL-cholesterol (72%), obesity (77%) and impaired glucose (73%) were similarly prevalent, with higher blood pressure, serum creatinine and Cornell product, but lower Sokolow-Lyon voltage (all Po0.001). After adjusting for baseline covariates, hazard ratios for CEPs and cardiovascular death (4.871.1 years follow-up) were 1.47 (95% confidence interval (CI), 1.27-1.71)-and 1.73 (95% CI, 1.38-2.17)-fold higher with MetS (both Po0.0001), and were only marginally reduced when further adjusted for diabetes, obesity, low HDL-cholesterol, non-HDL-cholesterol, pulse pressure and in-treatment systolic blood pressure and heart rate. Thus, MetS is associated with increased cardiovascular events in hypertensive patients with ECG-LVH, independently of single cardiovascular risk factors.
Introduction
The widely recognized need to manage global cardiovascular risk in patients with arterial hypertension has recently been reinforced by studies examining the effect of clusters of cardiovascular risk factors, a condition that has had several labels 1, 2 before a consensus has been reached to term it 'the metabolic syndrome'. [3] [4] [5] [6] [7] Despite recent evidence of a major impact on cardiovascular risk, [8] [9] [10] there is debate in the scientific community about whether identification of the metabolic syndrome improves prediction of cardiovascular events compared to use of single risk factors. [11] [12] [13] [14] Paralleling this debate, however, there is emerging evidence that the metabolic syndrome is associated with preclinical cardiovascular disease [15] [16] [17] [18] [19] [20] and higher rates of cardiovascular events, [8] [9] [10] suggesting that the metabolic syndrome may have more adverse cardiovascular effects than predicted by its individual components.
Recent findings suggest that the metabolic syndrome might also negatively influence prognosis in arterial hypertension 10, 21 and in the presence of overt cardiovascular disease. 9, 22 However, whether the metabolic syndrome maintains its prognostic value in the large population of hypertensive patients with left ventricular hypertrophy (LVH) 23 has never been documented. Accordingly, we assessed the prognostic impact of the metabolic syndrome in a cohort of hypertensive individuals with established electrocardiographic (ECG)-LVH in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Methods

Participants
Among the 9193 participants in the LIFE study, 24, 25 we selected 8243 with body mass index (BMI) X20 kg/m 2 26 and available laboratory data needed to assess lipid and glucose profiles at enrolment. General information on recruitment of the LIFE cohort and characteristics of participants have been reported previously. 24, 25 Participants were required to have sitting systolic blood pressure 160-200 mm Hg or diastolic blood pressure 95-115 mm Hg after 1 or 2 weeks of singleblind placebo treatment without other antihypertensive medication and to have ECG-confirmed LVH (by Cornell voltage-duration product or Sokolow-Lyon voltage). 25 Patients with myocardial infarction or stroke within 6 months, current heart failure or previously known left ventricular ejection fraction o40%, or serum creatinine 4160 mmol/l (41.81 mg/dl) were excluded. Prevalent cardiovascular disease was identified and adjudicated as reported previously. [26] [27] [28] In addition to randomized treatments (losartan or atenolol), other medications were used, including diuretics, calcium-channel blockers and other antihypertensive medications, excluding angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and b-blockers.
26
All patients signed informed consent documents, and the protocol was approved by all relevant ethics review committees.
Clusters of metabolic risk factors
The NCEP-ATPIII definition of metabolic syndrome 4 was modified for the present analyses to reflect availability of data (Table 1) . In this analysis, one component of metabolic syndrome, high blood pressure, was present in all participants at baseline. For definition of metabolic syndrome, therefore, two or more of the following risk factors were required: BMIX30 kg/m 2 , high-density lipoprotein (HDL)-cholesterol o1.0/1.3 mmol/l (o40/50 mg/dl) (men/ women), glucoseX6.1 mmol/l (X110 mg/dl) fasting or X7.8 mmol/l (X140 mg/dl) nonfasting, or diabetes. Diabetes was defined by 1985 WHO 29 criteria, according to investigator report and/or glucose level. Among LIFE participants, baseline glucose was not required to be collected fasting. Accordingly, glucose was considered elevated when X6.1 mmol/l (X110 mg/dl) in fasting or X7.8 mmol/l (X140 mg/dl) in nonfasting specimens (n ¼ 2441). The partition value for nonfasting glucose was decided based on findings from the United Kingdom Prospective Diabetes Study. 30 Waist circumference was not measured in the LIFE study and, therefore, BMIX30 kg/m 2 was used instead to define obesity. Lipid profile was assessed by sex-specific partitions of HDL-cholesterol. Triglycerides and low-density lipoprotein-cholesterol were not measured in the LIFE population. Non-HDL-cholesterol was computed (total cholesterol minus HDL-cholesterol), though it was not used for definition of metabolic syndrome.
Study design
The current analysis was not prespecified as part of the LIFE protocol; therefore, neither selection of patients nor treatment randomization was related to the presence or the absence of the metabolic syndrome. For this analysis, the LIFE population was divided into groups with or without the metabolic syndrome. We analysed the LIFE primary composite end point of cardiovascular death, fatal and nonfatal stroke, or fatal and nonfatal myocardial infarction (n ¼ 974), and cardiovascular death (n ¼ 387). End points were adjudicated by an independent end point committee on the basis of definitions provided in the LIFE study predefined end point manual. 27 Statistical analysis Data were analysed using SPSS 12 software (SPSS, Chicago, IL, USA). Descriptive statistics were obtained using w 2 distributions and one-factor analysis of variance. Skewed variables (urinary albumin/ creatinine ratio) were log transformed for compar- ison. Adjusted cumulative proportional hazard functions were computed by Cox regression and the corresponding curves displayed. Examination of predictors in multivariate analysis was performed by addition of potential confounders into a Cox model generated using age, sex, prevalent cardiovascular disease and the two ECG measures of LVH. In a second model also cardiovascular risk factors were added as covariates. Systolic blood pressure and heart rate were treated as time-varying covariates to take into account in-treatment levels. Hazard ratios with 95% confidence intervals (CI) and adjusted cumulative incidence of the primary composite end point and cardiovascular death are reported.
Results
Distribution of cardiovascular risk factors
Of the 8243 (4398 women) patients with BMIX 20 kg/m 2 and available laboratory data needed for assessment of lipid and glucose profiles, impaired glucose was detected in 2048 (24.8%, 1011 women) including 1033 patients with diabetes (12.5%, 553 women). Obesity was present in 2419 participants (29.3%, 1517 women; Po0.0001 vs men). Low HDLcholesterol was detected in 1899 participants (23%, 1106 women; Po0.0001 vs men). Overall, the metabolic syndrome was identified in 1591 individuals (19.3%, 948 women; Po0.0001 vs men).
Phenotypic characteristics of metabolic syndrome
The phenotypic presentation of the metabolic syndrome in the LIFE cohort was characterized by a balanced combination of cardiovascular risk factors. Obesity was present in 1227 of the 1591 subjects with the metabolic syndrome (77%), high glucose in 1156 (73%) and low HDL-cholesterol in 1152 (72%). Among participants with the metabolic syndrome, 1238 subjects (78%) exhibited a combination of two risk factors, whereas 353 (22%) had all three risk factors in addition to hypertension. Table 2 shows that subjects with the metabolic syndrome had higher baseline blood pressure. In addition to the expected differences between the variables defining metabolic syndrome, other relevant differences were found in heart rate, non-HDLcholesterol, serum creatinine and urinary albumin/ creatinine ratio. Cornell voltage-duration product was also significantly greater in the group with the metabolic syndrome, whereas Sokolow-Lyon voltage was lower. Similar results were found after excluding participants with diabetes (results not shown).
Survival analysis
During the mean 4.8. years of the study, 974 primary composite end points and 387 cardiovascular deaths occurred. The presence of metabolic syndrome was associated with a 1.4-fold higher risk of the primary composite end point (95% CI, 1.2-1.7) and 1.6-fold higher risk of cardiovascular death (95% CI, 1.3-2.1; both Po0.0001).
These higher risks were confirmed in proportional hazard analysis after adjusting for age, sex, prevalent cardiovascular disease and indices of ECG-LVH (hazard ratio ¼ 1.47 (95% CI, 1.27-1.71) for the primary composite end point; hazard ratio ¼ 1.73 (95% CI, 1.38-2.17) for cardiovascular death; both Po0.0001). Survival curves for the combined treatment groups ( Figure 1 ) showed a nearly 5% absolute increase in the primary composite end point and a 3% increase in cardiovascular death in the group with metabolic syndrome (both Po0.0001). Although randomization was not stratified by the presence of the metabolic syndrome, treatment allocation to losartan-or atenolol-based therapy was similar in both groups: losartan was given to 51.4% of subjects with the metabolic syndrome and to 50% of those without. The effect of randomized treatment was tested by introducing treatment into the Cox proportional hazard model. Table 3 shows that the increased risks of either the primary composite end point or cardiovascular death associated with the presence of the metabolic syndrome were not substantially modified by treatment. Table 3 also shows that losartan maintained a protective effect as compared with atenolol in reducing the risk of the composite end point by 15% (Po0.02), with a parallel, albeit less strong, trend Metabolic syndrome in hypertension and LVH G de Simone et al towards an 11% lower rate of cardiovascular death independent of the metabolic syndrome. We further examined the potential influence of pre-existing cardiovascular disease on prognostic effect of the metabolic syndrome by separately analysing participants with or without prevalent cardiovascular disease at the time of randomization. Prevalent cardiovascular disease was present in 2039 participants (24.7%), 53% of whom were randomized to losartan-based therapy. After adjusting for age, sex, indices of ECG-LVH and treatment, the presence of metabolic syndrome conferred a significantly higher risk of the composite end point to both participants without (hazard ratio ¼ 1.50 (95% CI, 1.23-1.83); Po0.0001) and with (hazard ratio ¼ 1.43 (95% CI, 1.14-1.78); Po0.002) preexisting cardiovascular disease. Similarly, the hazard for cardiovascular death was 1.91 (95% CI, 1.41-2.59; 
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Po0.0001) for participants without and 1.51 (95% CI, 1.08-2.11; Po0.02) for those with pre-existing cardiovascular disease.
Prognostic effect of metabolic syndrome, adjusting for risk factors
We addressed the question of whether the metabolic syndrome as a clinical entity adds to the considerations of single risk factors in the setting of arterial hypertension complicated by established end-organ damage. Eight new covariates were entered into the Cox model together with the other covariates displayed in Table 3 : baseline pulse pressure, timevarying heart rate and systolic blood pressure, obesity, diabetes, low HDL-cholesterol, non-HDLcholesterol and serum creatinine. The independent relations of the metabolic syndrome with the risk of the primary composite end point or cardiovascular death were unmodified by addition of the eight new factors into the model (Table 4) . To partially offset the lack of triglyceride levels and to improve the external validity of these findings, we selected 20% of participants in the group without metabolic syndrome, assuming that they could have metabolic syndrome if triglycerides were measured. These LIFE participants were selected on the basis of having the highest probability of having high triglyceride levels based on an empiric regression equation developed and tested in the HyperGEN population (from the Family Blood Pressure Program) 31, 32 and were added to the group with metabolic syndrome. This increased the prevalence of metabolic syndrome from 19 to 27% (2261 instead of 1591 participants). The Cox models shown in Table 4 were repeated after this classification, confirming significant hazard ratios of metabolic syndrome for composite cardiovascular events (1.30 (95% CI, 1.06-1.56), Po0.02) and for cardiovascular death (1.75 (95% CI, 1.31-2.33); Po0.0001).
Discussion
The present analysis demonstrates a strong negative prognostic effect of clustered metabolic alterations in a large population of hypertensive patients with LVH. These metabolic alterations include obesity, abnormal lipid profile and elevated glucose level, and are representative of the categories of risk factors included with, though not coincident with, those used in the definition of the metabolic syndrome. For simplicity, we have therefore used the term metabolic syndrome to define the studied clustered metabolic abnormalities.
The predictive value of metabolic syndrome in the LIFE cohort is maintained in participants with or without pre-existing cardiovascular disease, and is also maintained when the main risk factors included in the definition of the syndrome are considered in the hazard model. This effect is evident for both composite cardiovascular end points and for cardiovascular death, and is only marginally attenuated by consideration of diabetes, obesity, low HDLcholesterol and differences in heart rate. It is also independent of indices of ECG-LVH, serum creatinine and pulse pressure, which may be considered as markers of preclinical cardiovascular disease. 33 Thus, in a large cohort of hypertensive patients with preclinical or clinically overt cardiovascular disease, the metabolic syndrome contributes to Metabolic syndrome in hypertension and LVH G de Simone et al increased cardiovascular events in addition to, and independently of, its component risk factors and established end-organ damage. As compared with our previous analysis demonstrating that moderateto-severe obesity independently predicts cardiovascular risk in the LIFE cohort, 26 this analysis of metabolic syndrome suggests that at least part of the effect of obesity is attributable to clusters of cardiovascular risk factors coexisting with obesity. Interestingly, diabetes maintains a potent negative effect on prognosis.
The prognostic effect of the metabolic syndrome in addition to single risk factors could already be postulated in previous studies. In the Third National Health and Nutrition Examination Survey, 34 the ageadjusted prevalence of coronary heart disease in the population over 50 years of age was 8% in participants with diabetes but no metabolic syndrome, similar to 9% in subjects without diabetes or metabolic syndrome. In contrast, the prevalence of coronary heart disease increased to 14% in nondiabetic subjects with metabolic syndrome, and to 19% in those with both conditions. In the Kuopio Heart Study, 8 participants with metabolic syndrome exhibited a 2.1-fold higher risk of all-cause mortality and a 3.6-fold higher risk of cardiovascular mortality than those without the metabolic syndrome independent of the presence of type II diabetes over a follow-up of 9-20 years. These results raise the question of whether the cardiovascular risk associated with type II diabetes is a primary effect of the impaired glucose homeostasis or instead reflects the concomitant presence of the metabolic syndrome in most diabetic individuals. 35 The quoted studies 8, 34 were conducted in unselected populations, leaving the question open of whether or not the metabolic syndrome-associated cardiovascular risk could also be identified at the highest level of cardiovascular risk, in the presence of preclinical cardiovascular disease, a more advanced step in the evolution of natural history of cardiovascular disease. 36 Our results show that the negative effect of clusters of metabolic risk factors constituting the metabolic syndrome is also evident when LVH has developed. It is even more relevant that, at least in the studied context, the metabolic In the LIFE study, the prevalence of the metabolic syndrome was less than could be expected from epidemiologic surveys, 5, 34 though not substantially different from the prevalence recently reported in Italy. 37 The relatively lower prevalence of the metabolic syndrome in the LIFE cohort was at least in part the effect of the lack of triglycerides as one of the factors participating in the definition, which reduces the sensitivity of our selection as compared with the ATPIII criteria. 38 However, a simulation performed increasing the number of participants with metabolic syndrome, by selecting those with greater probability of high triglycerides level, and under the assumption that 20% of subjects could have been misclassified did not modify the result. Another important difference from the ATPIII definition was the substitution of waist circumference with BMI. While maintaining specificity of detection of abdominal adiposity (nearly all individuals with BMIX30 mg/m 2 have central fat distribution), this different definition of obesity might have further reduced sensitivity of detecting abnormalities, especially in women. Taken overall, these differences are likely to have contributed to select a high-risk subclass of metabolic syndrome, which is further aggravated by the coexistence of established end-organ damage (ECG-LVH).
The characteristics of the LIFE study raise questions about the generalizability of our results to populations with different features, an issue that needs to be explored. However, even considering the LIFE study characteristics as limitations, the impact of our findings on cardiovascular prevention might be relevant because 7.8 million inhabitants in 15 European countries are expected to meet the main LIFE study inclusion criteria (including age range, presence of LVH by the same ECG criteria and absence of heart failure), with similar numbers in the rest of Europe and the United States. 23 If the multiplicative effect of clusters of cardiovascular risk factors is confirmed, biological mechanisms of damage amplification should be investigated.
In conclusion, the metabolic syndrome is associated with a high-risk phenotype and increases risk of cardiovascular morbidity and mortality in hypertensive individuals with ECG-LVH, independently of demographic confounders, single risk factors and markers of preclinical cardiovascular disease.
